The group of patients was then divided based on hormone receptor (HR) status, defined as negative when HER2, ER, and PR were negative (HR−/triple-negative breast cancer (TNBC)), and positive when ER and/or PR were positive (HR+). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.